Evaluation of the Therapeutic Approaches Impacting on the Survival of Patients with an Advanced Pancreatic Neuroendocrine Tumor
Abstract #1361

Introduction: The therapeutic approaches in metastatic pancreatic neuroendocrine tumors (pNET) are currently used as a palliative strategy to control symptoms and potentially improving patient survival.

Aim(s): We evaluated the impact of different treatments on the survival of well-differentiated metastatic pNET patients (pts).

Materials and methods: Retrospective study of variables in a consecutive multicenter cohort (n=312) of pathologically confirmed, sporadic, well-differentiated metastatic pNET pts diagnosed between 1993 to 2010. The minimum follow-up was set at 5 years.

Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.

Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET

To continuously improve user experience - only with your consent - your data will be transmitted to Google Analytics. You can find out all relevant information on the use of cookies in our privacy policy.